Kenvue (KVUE) Earnings Date & Reports

Key Takeaways

• Net sales reached $3.96 billion in the fiscal second quarter ended June 28, 2026, up 3.0% year-over-year, marking the third consecutive quarter of net and organic sales growth.
• Adjusted diluted earnings per share (EPS) rose 7% to $0.31, while GAAP diluted EPS increased 9% to $0.24; both fell slightly short of Wall Street consensus estimates.
• Gross and operating margins contracted as inflation, tariffs, and unfavorable foreign exchange outweighed supply chain savings and pricing gains.
• Skin Health and Beauty led all segments with 5.1% net sales growth, driven by strong demand for Neutrogena and OGX hair and face care products.
• No forward guidance was provided due to the pending $40 billion acquisition by Kimberly-Clark, expected to close in the fourth quarter of 2026.
• Shares declined approximately 2.5% on the day of the release, reflecting investor disappointment over the top- and bottom-line misses.

Earnings Context and Why It Matters

Kenvue's fiscal second-quarter 2026 results landed at a pivotal moment for the world's largest pure-play consumer health company. The report comes as Kenvue navigates its pending $40 billion acquisition by Kimberly-Clark, a deal that has reshaped how investors evaluate the stock. With the company opting not to hold a quarterly earnings call and suspending forward-looking guidance, this earnings release served as one of the few remaining windows into standalone operational performance before the expected merger closes later this year. The results provide a snapshot of how Kenvue's iconic brands — including Tylenol, Listerine, Neutrogena, and Band-Aid — are performing amid persistent inflationary pressures, tariff impacts, and a dynamic consumer spending environment.

Reported Results

Kenvue reported net sales of $3.955 billion for the fiscal second quarter ended June 28, 2026, representing a 3.0% increase from $3.839 billion in the prior-year period. The result came in below the analyst consensus estimate of approximately $4.045 billion. Organic sales — a non-GAAP (Generally Accepted Accounting Principles) measure that strips out currency effects and acquisitions — grew 1.6%, reflecting 0.9% favorable value realization from pricing and product mix and 0.7% volume growth, alongside a 1.4% foreign currency tailwind.

On the bottom line, GAAP diluted EPS came in at $0.24, up 9% from $0.22 a year earlier. Adjusted diluted EPS rose 7% to $0.31, up from $0.29 in the prior-year period. However, this fell roughly 4.8% below the $0.32 to $0.33 consensus estimate compiled by analysts. Net income climbed to $456 million from $420 million in the year-ago quarter.

Profitability metrics softened across the board. Gross profit margin declined to 58.2% from 58.9%, while adjusted gross margin slipped to 60.2% from 60.9%. Operating income margin edged down to 17.7% from 18.0%, with the adjusted figure at 22.1% versus 22.7% a year ago. Management attributed the margin compression to inflation, tariffs, unfavorable transactional foreign exchange, and increased brand support spending, partially offset by productivity gains from global supply chain optimization initiatives and cost-saving actions under the company's restructuring plan.

All three operating segments posted year-over-year growth. Self Care net sales rose 2.2% to $1.59 billion, supported by improved Tylenol consumption trends in the U.S. and market share gains for Zyrtec and Pepcid. Skin Health and Beauty delivered the strongest performance with a 5.1% increase to $1.11 billion, powered by hair and face care products under the OGX and Neutrogena banners. Essential Health grew 2.3% to $1.25 billion, with wound care and baby care offsetting a modest decline in oral care. First-half free cash flow surged to $1.0 billion, up from $800 million in the comparable 2025 period.

AI Screener

For investors seeking to navigate earnings season with greater efficiency, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool allows traders and investors to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether scanning for breakout candidates, tracking earnings momentum, or identifying stocks exhibiting specific chart formations, the AI Screener helps users surface relevant opportunities far more efficiently than manual screening methods. It is built to support data-driven decision-making across a wide range of investing styles and time horizons.

Market Reaction and Investor Sentiment

Kenvue shares declined approximately 2.5% to 2.7% on August 6, closing at $19.18, as investors digested a mixed earnings report that fell short of Wall Street expectations on both revenue and adjusted EPS. The pre-market indication had pointed to a similar decline, and the stock held those losses through the regular session. The negative reaction ended a four-quarter streak of earnings beats for the consumer health company.

Sentiment was further tempered by the absence of a quarterly conference call and the withdrawal of forward guidance — both consequences of the pending Kimberly-Clark acquisition. Without management commentary on outlook, investors were left to interpret the raw numbers against a backdrop of tariff uncertainty, currency volatility, and evolving consumer demand patterns. The broader market appeared to weigh margin durability concerns more heavily than the company's third consecutive quarter of organic sales growth.

Forward Outlook and Key Factors to Monitor

Looking ahead, the single most consequential event for Kenvue shareholders is the expected completion of the $40 billion acquisition by Kimberly-Clark in the fourth quarter of 2026. The deal remains subject to foreign regulatory approvals and other customary closing conditions. Until the transaction closes, Kenvue will not issue forward guidance, eliminating a key visibility anchor for investors and shifting attention entirely to the consummation timeline and any regulatory hurdles that may arise.

Beyond the merger, several operational themes warrant attention. Margin resilience will remain in focus as inflation and tariff pressures persist across Kenvue's global supply chain. The company's restructuring program — expected to generate approximately $250 million in pre-tax charges during 2026 — is designed to streamline operations, enhance supply chain efficiency, and lower the cost base. The pace at which these savings materialize could meaningfully influence profitability in the quarters ahead.

On the product front, Kenvue continues to benefit from innovation-driven momentum. Recent launches such as OGX Pro Growth+ Peptide, Neutrogena Ultra Sheer Sun, Band-Aid PRO HEAL 5 Day Protect, and Listerine On-The-Go sachets are contributing to volume growth across segments. The FDA approval of a combination acetaminophen-naproxen sodium over-the-counter pain medicine under the Tylenol brand adds another potential growth lever. Sustaining these innovation pipelines and maintaining strong e-commerce momentum will be critical, regardless of the ownership structure.

Investors should also monitor consumer health spending trends, particularly in North America, where Kenvue generates a significant portion of its revenue. Any softening in discretionary categories such as skin care and beauty could create headwinds even as essential health staples like wound care and baby care provide a stable floor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations